Biogen Inc.
BIIB· Nasdaq
BIIBBiogen Inc.
Filed Feb 3, 2022 · 10-K · 34 days after period end · 0000875045-22-000007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $2.73B | $2.85B | $3.67B | $3.53B |
| Net Income | $368.20M | $357.90M | $1.44B | $946.80M |
| EPS Diluted | — | $2.32 | $8.08 | $4.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 3, 2022 · 34 d after period end
